In a January 15th filing, Representative Julie Johnson (D-Texas) disclosed the sale of between $1,001 and $15,000 in UnitedHealth Group stock on December 18th from her ChASE Brokerage Account (3935). This transaction represents the first UNH trade attributed to Johnson since she assumed office in January 2025. The timing of her sale coincided with additional dispositions in Texas Instruments, General Dynamics, PepsiCo and other large-cap names, prompting investor interest in whether her actions reflect policy insights or portfolio rebalancing ahead of proposed healthcare legislation expected in early 2026.

UnitedHealth Group reported third-quarter revenue of $113.16 billion, a 12.2% year-over-year increase, and GAAP EPS of $2.92, beating consensus estimates by $0.05. The company delivered a return on equity of 19.23% and maintained a net margin of 4.04%. On December 16th, UNH paid its quarterly dividend of $2.21 per share to record holders as of December 8th, translating into an $8.84 annualized payout and a yield of 2.7%. Management reiterated guidance for full-year adjusted EPS around $29.50, underpinned by continued membership growth in Medicare Advantage and Optum services expansion.

Institutional ownership remains robust at 87.9%, with North Capital Inc. and Sunflower Bank N.A. among those increasing holdings by 16.2% and 1.5%, respectively, during the third quarter. Axis Wealth Partners and Abound Wealth Management also added to positions, reflecting confidence in UNH’s long-term cash flows. On the sell-side, Sanford C. Bernstein and Leerink Partners have raised their price targets to $440 and $410 respectively, maintaining outperform ratings. MarketBeat’s consensus calls UNH a Moderate Buy, with analysts highlighting a P/E ratio near 17.3 and a PEG of 2.0 as attractive entry metrics for healthcare investors.